Abstract
Therapeutic administration of interleukin-2 (IL-2) in patients with metastatic cancer disease has been shown to lead to tumor regression [1]. This therapeutic approach is associated with the activation of cytotoxic cell populations [2], proliferation of various lymphocyte subsets [3], and induction of secondary cytokines released by different effectors of the human immunes system [4].
This work was supported by the Bundesministerium für Forschung und Technologie (Grant 01GA8802), Cilly-Weilstiftung, Riese-Stiftung and the Paul and Ursula Klein Stiftung.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitmann S, Linehan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
Bergmann L, Mitrou PS, Weidmann E, Schmidt-Matthiesen A, Hanke P, Hoelzer D (1989) In vitro and in vivo induction of lymphokine activated killer (LAK) cells in patients with gastric cancer and other solid tumors. In: Koldovsky et al. (eds) Lymphocytes in immunotherapy of cancer. Springer, Berlin Heidelberg New York, pp 32–43
Weidmann E, Bergmann L, Christ S, Mitrou PS, Bank H (1988) Follow-up of lymphocyte subsets after in vitro and in vivo application of recmobinant interleukin-2 (rIL-2) and the induction of LAK-activity within different lymphocyte subsets. Blut 57:259
Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA (1985) In vivo administration of purified Interleukin-2. II. Half-life immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135:2865–2875
Ferrini S, Miescher S, Zocchi MR, von Fliedner V, Moretta A (1987) Phenotypic and functional characterization of recombinant Interleukin-2 (rIL-2) induced activated killer cells: analyses at the population and clonal levels. J Immunol 138:1297–1302
Tilden AB, Itoh K, Balch CM (1987) Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. J Immunol 138:1068–1073
Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL (1987) In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined Interleukin-2 and LAK-cell therapy. J Clin Oncol 139:1933–1941
Bol SJ, Rosendorf HS, Rontelap CP, Hennen LA (1986) Cellular cytotoxicity, assessed by the Cr51-release assay. J Immunol Methods 90:15–23
Parkinson DR (1988) Interleukin-2 in cancer therapy. Semin Oncol 316:10–26
Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF (1988) Characterization of functional surface structures on human natural killer cells. Adv Immunol 42:181–211
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Weidmann, E., Bergmann, L., Hechler, P., Schwulera, U., Grieser, H., Mitrou, P.S. (1993). Interleukin-2 in the Treatment of Cancer Disease: Introduction of a Therapeutic Model and some Immunological Data. In: Fleischer, J. (eds) Leukemias. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77083-8_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-77083-8_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77085-2
Online ISBN: 978-3-642-77083-8
eBook Packages: Springer Book Archive